英派药业拟港股上市 中国证监会要求补充说明历次增资及股权转让定价依据等事项

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas listing applications, specifically addressing Nanjing Inpai Pharmaceutical Co., Ltd. and its compliance with various regulatory aspects [1][2]. Group 1: Regulatory Requirements - The CSRC has requested Inpai Pharmaceutical to clarify the pricing basis for its past capital increases and equity transfers, and to confirm whether there have been any violations regarding capital contributions or shareholding legality [1] - The company is also required to provide details on the compliance of its three overseas subsidiaries with foreign investment and foreign exchange registration regulations [1] - Additionally, the CSRC seeks confirmation on whether there have been any instances of shareholding representation since the company's establishment [1] Group 2: Shareholder Compliance - The company must disclose whether any shareholders holding more than 5% of shares have any domestic entities that are prohibited from holding shares under relevant laws and regulations [1] Group 3: Business Operations and Compliance - Inpai Pharmaceutical is required to explain its business scope and operations in relation to human stem cells, gene diagnosis, and treatment technologies, ensuring compliance with foreign investment policies [2] - The company must also confirm that its proposed issuance plan aligns with the regulatory guidelines for overseas listings and clarify the status of shares held by shareholders participating in the "full circulation" [2] Group 4: Company Overview - Inpai Pharmaceutical, established in 2009, is a biotechnology company focused on the global development of precision cancer therapies based on synthetic lethality mechanisms [2] - The company has developed a comprehensive and advanced portfolio of synthetic lethality products and is one of only three companies globally with both commercialized PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors [2] - Its core product, Senaparib, is a PARP1/2 inhibitor approved in January 2025 for first-line maintenance treatment of ovarian cancer in China, demonstrating the greatest progression-free survival benefit among approved PARP inhibitors for this indication [2]